Document is current
Any future updates will be listed below
-
Authors
Chatterjee, Pratishtha http://orcid.org/0000-0003-4877-1958
Pedrini, Steve
Stoops, Erik
Goozee, Kathryn http://orcid.org/0000-0002-3573-1554
Villemagne, Victor L.
Asih, Prita R.
Verberk, Inge M. W. http://orcid.org/0000-0003-0341-7445
Dave, Preeti
Taddei, Kevin
Sohrabi, Hamid R.
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Teunissen, Charlotte E.
Vanderstichele, Hugo M.
Martins, Ralph N. http://orcid.org/0000-0002-4828-9363
-
Funding
Funding for this research was provided by:
Svenska Forskningsrådet Formas (2018-02532, 2017-00915)
Alzheimer’s Drug Discovery Foundation (RDAPB-201809-2016615)
- License Information
-
More Information
Article History
Received: 2 July 2020
Revised: 26 September 2020
Accepted: 7 October 2020
First Online: 11 January 2021
Conflict of interest
: E.S. is an employee of ADx NeuroSciences. HRS has received ruminations for working with Pfizer and Takeda. H.Z. has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. H.M.V. is a co-founder of ADx NeuroSciences and a founder of Biomarkable. All other authors report no conflict of interest in relation to the current study.
